Navigation Links
Medivation Announces Participation in 27th Annual J.P. Morgan Healthcare Conference
Date:1/8/2009

SAN FRANCISCO, Jan. 8 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that David Hung, M.D., president and chief executive officer, will present at the 27th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, at 10:00 a.m. Pacific Time at the Westin St. Francis Hotel in San Francisco.

Dr. Hung will provide an overview of Medivation and its clinical development programs for Dimebon for Alzheimer's and Huntington's diseases and MDV3100 for prostate cancer.

A live audio webcast will be available on the "Events and Presentations" page of the "Investor Relations" section of the Company's website at http://www.medivation.com. A replay also will be available for 30 days following the live presentation.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation entered into a global agreement with Pfizer Inc to develop and commercialize Dimebon for the treatment of Alzheimer's and Huntington's diseases. With Pfizer, the Company is conducting a broad Dimebon clinical development program, including a pivotal and confirmatory Phase 3 trial, known as the CONNECTION study, in patients with mild-to-moderate Alzheimer's disease. The program also includes additional trials planned to begin this year in Alzheimer's disease, as well as further development of Dimebon in patients with mild-to-moderate Huntington's disease. In addition, a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also
'/>"/>

SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Medivation to Announce Early Positive Data from Phase 1-2 Hormone Refractory Prostate Cancer Trial and Host Conference Call and Webcast on Monday, November 5, 2007
2. Medivation Plans to Initiate Pivotal Confirmatory Phase 3 Trial of Dimebon(TM) for Alzheimers Disease in Second Quarter of 2008
3. Medivation to Present at Cowen and Companys 28th Annual Health Care Conference
4. Medivation Announces Participation in Upcoming Conferences
5. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
6. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
7. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
8. HEI, Inc. Announces Sale of RFID Division Assets
9. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
10. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
11. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Centre for Accident Research & Road Safety - Queensland ... in Transport Conference (OSIT) which is being held on ... Blackman, a CARRS-Q road safety researcher, said speed limit ... limits and related traffic controls remained in place at ... If people are asked to slow down at roadwork ...
(Date:9/19/2014)... Lifeinsure.biz has released a new ... can be purchased without medical examinations. , Life ... a life insurance policy more advantageous. Clients can read ... extra options available for a no medical exam life ... required is simple to purchase, however it is more ...
(Date:9/19/2014)... 19, 2014 Outsourcing services provider Profit By ... US IT conglomerate to provide HR outsourcing services in India. ... an exclusive partner and will act as a talent acquisition ... deploy over 120 personnel across 3 locations in India in ... , "This is a significant win for us and we ...
(Date:9/19/2014)... 2014 Kyrgyzstan has one of ... To reduce the burden of tuberculosis (TB) and ... Kyrgyz Republic, Abt Associates has been awarded the ... Program under a five-year cooperative agreement with total ... support universal and equitable access to high-quality TB ...
(Date:9/19/2014)... Quincy Bioscience is pleased to announce ... private practice in Mequon, Wis., is presenting data ... adults with mild memory problems at the ... conference on Sept. 19-20 in Hollywood, Fla. ... of the jellyfish protein apoaequorin-containing supplements. Prevagen Professional ...
Breaking Medicine News(10 mins):Health News:Don't cry wolf: Drivers fed up with slowing down at inactive roadwork sites 2Health News:No Medical Exam Life Insurance - Lifeinsure.biz Presents 5 Important Riders! 2Health News:Profit By RPO Bags huge RPO contract from US-based Implementation Partner 2Health News:New Project Aims to Reduce Burden of Tuberculosis in the Kyrgyz Republic 2Health News:Prevagen Research Presented at Healthcare Practitioner Conference 2
... disease, rheumatoid arthritis (RA) is characterized by persistent inflammation ... Beyond loss of mobility, sufferers face a high risk ... contributing to the development of RA, tumor necrosis factor ... Inhibition of TNFa has opened promising new treatment ...
... DALLAS Feb. 28, 2008 UT Southwestern Medical ... operation requiring only a single incision in the bellybutton ... It is the first such operation in North Texas. ... Homero Rivas, assistant professor of surgery, who completed the ...
... Actavis Group, the,international generic pharmaceuticals company, has ... Food & Drug Administration., The four products ... equivalent of,Bontril(R) tablets by Valeant Pharmaceuticals, are indicated ... of Phendimetrazine tartrate tablets,had annual sales of US$3.1 ...
... 40.6%, ETHEX Revenue Up 57.8% for Third Quarter, Up ... Revenue Up 16.6% for Third Quarter, Up 15.2% ... KV Pharmaceutical Company,(NYSE: KVa/KVb) today reported preliminary financial results ... 2008 ended December 31, 2007. The,results reflected continued acceleration ...
... the Robert Wood Johnson Foundation, has launched the Network for ... study health care disparities affecting minorities with chronic diseases. ... a new generation of researchers with an expertise in health ... to be directed by Dr. Michael Rodrguez, associate professor of ...
... drop in a severe form of the disorder, , , WEDNESDAY, Feb. ... decreasing, and a more severe form of the disease caused by ... Those are the two main findings from a Massachusetts study that ... and 35 babies a year before 2003 to less than 20 ...
Cached Medicine News:Health News:Effect of tumor necrosis factor a inhibitors on heart failure risk in RA Patients 2Health News:Effect of tumor necrosis factor a inhibitors on heart failure risk in RA Patients 3Health News:UT Southwestern surgeons complete North Texas' first single-incision gallbladder removal 2Health News:UT Southwestern surgeons complete North Texas' first single-incision gallbladder removal 3Health News:Actavis Extends Portfolio With Four New Products in the U.S. 2Health News:KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis 2Health News:KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis 3Health News:KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis 4Health News:KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis 5Health News:KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis 6Health News:KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis 7Health News:KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis 8Health News:KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis 9Health News:KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis 10Health News:KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis 11Health News:UCLA launches network to study health care disparities affecting minorities 2Health News:Newborn Screening Suggests Decline in Cystic Fibrosis 2Health News:Newborn Screening Suggests Decline in Cystic Fibrosis 3
(Date:9/18/2014)... Sept. 18, 2014  Low T Center endorses ... in Hyattsville, Maryland earlier ... the proper patient population for testosterone therapy (TRT), ... associated with TRT. Examining recent claims from studies that ... "available epidemiological studies do not provide convincing evidence ...
(Date:9/18/2014)... 18, 2014   MacPractice,s MacPractice MD MU ... EHR certification, which designates that the software is capable ... and Stage 2 Meaningful Use measures required to qualify ... (ARRA).  MacPractice MD MU version 5.0 was certified on ... Office of the National Coordinator-Authorized Certification Body (ONC-ACB) and ...
(Date:9/18/2014)... 2014 This BCC Research report discusses the medical device ... growth and size, and opportunities for different devices and regions. ... Patent analysis in the report focuses on technological trends in ... Europe and Japan . ... the global medical device technologies market. - Analyze market structure, ...
Breaking Medicine Technology:Low T Center Endorses The Joint FDA Committee Meeting on Testosterone 2MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 2MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 3MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 4MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 5Medical Devices: Technologies and Global Markets 2Medical Devices: Technologies and Global Markets 3Medical Devices: Technologies and Global Markets 4
... , , , , NASHVILLE, Tenn. and ... find that 70 percent of surveyed pharmacy directors expect to ... of chronic pain. Tanezumab, which is expected to be the ... under medical supervision, will likely be covered as a medical ...
... , , , SAN DIEGO, INDIANAPOLIS, and CAMBRIDGE, Mass., Dec. ... ), Eli Lilly and Company (NYSE: LLY ) ... results from a head-to-head study comparing exenatide once weekly, an ... in patients with type 2 diabetes. After 24 weeks of ...
Cached Medicine Technology:Majority of Surveyed Pharmacy Directors Expect To Cover Pfizer's Tanezumab If It Is Approved for the Treatment of Chronic Pain 2Majority of Surveyed Pharmacy Directors Expect To Cover Pfizer's Tanezumab If It Is Approved for the Treatment of Chronic Pain 3Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 2Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 3Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 4Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 5Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 6Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 7
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: